Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes
- 1 June 2007
- journal article
- research article
- Published by American Physiological Society in American Journal of Physiology-Endocrinology and Metabolism
- Vol. 292 (6), E1775-E1781
- https://doi.org/10.1152/ajpendo.00624.2006
Abstract
Elevated plasma FFA cause β-cell lipotoxicity and impair insulin secretion in nondiabetic subjects predisposed to type 2 diabetes mellitus [T2DM; i.e., with a strong family history of T2DM (FH+)] but not in nondiabetic subjects without a family history of T2DM. To determine whether lowering plasma FFA with acipimox, an antilipolytic nicotinic acid derivative, may enhance insulin secretion, nine FH+ volunteers were admitted twice and received in random order either acipimox or placebo (double-blind) for 48 h. Plasma glucose/insulin/C-peptide concentrations were measured from 0800 to 2400. On day 3, insulin secretion rates (ISRs) were assessed during a +125 mg/dl hyperglycemic clamp. Acipimox reduced 48-h plasma FFA by 36% ( P < 0.001) and increased the plasma C-peptide relative to the plasma glucose concentration or ΔC-peptide/Δglucose AUC (+177%, P = 0.02), an index of improved β-cell function. Acipimox improved insulin sensitivity (M/I) 26.1 ± 5% ( P < 0.04). First- (+19 ± 6%, P = 0.1) and second-phase (+31 ± 6%, P = 0.05) ISRs during the hyperglycemic clamp also improved. This was particularly evident when examined relative to the prevailing insulin resistance [1/(M/I)], as both first- and second-phase ISR markedly increased by 29 ± 7 ( P < 0.05) and 41 ± 8% ( P = 0.02). There was an inverse correlation between fasting FFA and first-phase ISR ( r2= 0.31, P < 0.02) and acute (2–4 min) glucose-induced insulin release after acipimox ( r2=0.52, P < 0.04). In this proof-of-concept study in FH+ individuals predisposed to T2DM, a 48-h reduction of plasma FFA improves day-long meal and glucose-stimulated insulin secretion. These results provide additional evidence for the important role that plasma FFA play regarding insulin secretion in FH+ subjects predisposed to T2DM.Keywords
This publication has 50 references indexed in Scilit:
- Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialThe Lancet, 2006
- Palmitic acid-induced activation of human T-lymphocytes and aortic endothelial cells with production of insulin receptors, reactive oxygen species, cytokines, and lipid peroxidationBiochemical and Biophysical Research Communications, 2006
- Influence of Extended-Release Nicotinic Acid on Nonesterified Fatty Acid Flux in the Metabolic Syndrome With Atherogenic DyslipidemiaThe American Journal of Cardiology, 2005
- Potential Role of Oral Thiazolidinedione Therapy in Preserving ??-Cell Function in Type 2 Diabetes MellitusDrugs, 2005
- The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitusJCI Insight, 1999
- The effects of free fatty acids on gluconeogenesis and glycogenolysis in normal subjectsJCI Insight, 1999
- Impact of nicotinic acid treatment on insulin secretion and insulin sensitivity in low and high insulin respondersScandinavian Journal of Clinical and Laboratory Investigation, 1996
- Long-term exposure of rat pancreatic islets to fatty acids inhibits glucose-induced insulin secretion and biosynthesis through a glucose fatty acid cycle.JCI Insight, 1994
- Early Metabolic Defects in Persons at Increased Risk for Non-Insulin-Dependent Diabetes MellitusNew England Journal of Medicine, 1989
- Relationship between insulin-mediated glucose disposal and lipid metabolism in man.JCI Insight, 1985